Renee Aguiar-Lucander

Renee Aguiar-Lucander has extensive work experience in various roles and companies. Renee is currently the Chief Executive Officer at Calliditas Therapeutics AB since April 2017. Prior to this, they have held the role of Director at RAL Capital Ltd, where they served as a Non-Executive Director and Chairman for innovative growth companies from September 2015 to March 2021. Additionally, they have been the Managing Partner at Positive Capital Partners, providing project-based strategic and financing services for growth companies, from March 2016 to January 2021.

Before these positions, Renee served as the CEO of Pharmalink AB from April 2017 to November 2017. Renee also worked as a Partner at Omega Fund Management from January 2009 to June 2015, and as a Partner in the Venture Group at 3i Group plc, responsible for European legacy healthcare portfolio and publicly traded securities, from 2004 to 2008.

Prior to their venture capital roles, Renee held senior positions at Lehman Brothers as the Managing Director and Group Head from 1999 to 2003, at BT Alex. Brown as an Executive Director from 1997 to 1999, and at Alex. Brown & Sons as a Vice President from 1992 to 1997.

Renee Aguiar-Lucander has a solid education background in the field of business and finance. Renee obtained their MBA in Business Administration and Management from INSEAD in 1992. Prior to that, they completed their BA degree in Accounting and Finance from Stockholm School of Economics between 1982 and 1985.

In addition to their formal education, Renee Aguiar-Lucander holds certifications such as the Series 63 from NASAA and the Series 7 from the Financial Industry Regulatory Authority (FINRA). The exact dates of when they obtained these certifications are not specified.